array:22 [ "pii" => "S1889183722000848" "issn" => "18891837" "doi" => "10.1016/j.hipert.2022.11.002" "estado" => "S300" "fechaPublicacion" => "2023-04-01" "aid" => "507" "copyright" => "SEH-LELHA" "copyrightAnyo" => "2022" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Hipertens Riesgo Vasc. 2023;40:55-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S1889183722000812" "issn" => "18891837" "doi" => "10.1016/j.hipert.2022.09.003" "estado" => "S300" "fechaPublicacion" => "2023-04-01" "aid" => "504" "copyright" => "SEH-LELHA" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Hipertens Riesgo Vasc. 2023;40:58-64" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Arterial hypertension diagnosis: A problem?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "58" "paginaFinal" => "64" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Diagnóstico de hipertensión arterial: ¿un problema?" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Serrat-Costa, G. Coll de Tuero, C. Bertran Noguer, R. Martí Lluch, R. Ramos Blanes, A. Baltasar Bagué, W. Ricart" "autores" => array:7 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Serrat-Costa" ] 1 => array:2 [ "nombre" => "G." "apellidos" => "Coll de Tuero" ] 2 => array:2 [ "nombre" => "C." "apellidos" => "Bertran Noguer" ] 3 => array:2 [ "nombre" => "R." "apellidos" => "Martí Lluch" ] 4 => array:2 [ "nombre" => "R." "apellidos" => "Ramos Blanes" ] 5 => array:2 [ "nombre" => "A." "apellidos" => "Baltasar Bagué" ] 6 => array:2 [ "nombre" => "W." "apellidos" => "Ricart" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1889183722000812?idApp=UINPBA00004N" "url" => "/18891837/0000004000000002/v3_202307241519/S1889183722000812/v3_202307241519/en/main.assets" ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Counteracting aldosterone in cardiorenal disease in type 2 diabetes through finerenone administration" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "55" "paginaFinal" => "57" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "L.M. Ruilope, G. Ruiz-Hurtado" "autores" => array:2 [ 0 => array:4 [ "nombre" => "L.M." "apellidos" => "Ruilope" "email" => array:1 [ 0 => "ruilope@icloud.com" ] "referencia" => array:4 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 3 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "G." "apellidos" => "Ruiz-Hurtado" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Cardiorenal Translational Laboratory, Institute of Research i+12, Hospital Universitario 12 de Octubre, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "School of Doctoral Studies and Research, European University of Madrid, Madrid, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Contrarrestar la aldosterona en la enfermedad cardiorrenal en la diabetes tipo 2 mediante la administración de finerenona" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Blockade of the renin angiotensin system (RAS) has been classically used as the initial treatment in patients with type 2 diabetes (T2D) with cardiorenal disease to facilitate blood pressure (BP) control and the simultaneous cardiovascular and kidney protection. Albeit the demonstration of the role of aldosterone has been extensively proven in experimental studies, the presence of elevated circulating aldosterone levels and the prevalence of primary aldosteronism in hypertensive patients with or without T2D indicate that aldosterone frequently plays a significant role promoting simultaneously cardiac and renal damage in humans that had not been properly investigated in clinical studies.<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">1–3</span></a> In fact, in chronic kidney disease (CKD) only data indicating an important anti-proteinuric capacity with the use of mineralocorticoid receptor antagonists (MRAs) alone or on top of RAS blockade, have been demonstrated before the data of the new non-steroidal MRA finerenone were published.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Finerenone is a novel non-steroidal MRA with high receptor selectivity and affinity overcoming the capacities of spironolactone and eplerenone while avoiding importantly the risk of hyperkalemia.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">4</span></a> The initial trial on the effect of finerenone on albuminuria in patients with diabetic nephropathy most receiving a RAS blocker demonstrated a relevant improvement in the urinary albumin–creatinine ratio.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">5</span></a> These data open the door to the performance of two big clinical trials with 5734 and 7437 devoted, the first denominated the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial that preferentially investigated the capacity of renal protection,<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">6</span></a> and the second the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial that preferentially investigated the capacity of cardiovascular protection of finerenone.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">7</span></a> The initial planning also contemplated the simultaneous analysis including the data of the two trials that originated The FInerenone in chronic kiDney diseasE and type 2 diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial programme analYsis (FIDELITY) study<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a> that in our opinion constitutes the main influence for the future use of finerenone in clinical practice. In fact, the number of published articles related to finerenone containing data from FIDELITY are more numerous.</p><p id="par0015" class="elsevierStylePara elsevierViewall">The main findings of the FIDELIO-DKD trial demonstrated that finerenone resulted in a lower risk of CKD progression (18%) and cardiovascular events (24%) than placebo.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">6</span></a> This was accompanied by a decrease in albuminuria oscillating between 29.3 and 41.3% and by the presence of serious hyperkalemia in only 1.6% in patients treated with finerenone that exhibited an estimated glomerular filtration rate (eGFR) of 44.4<span class="elsevierStyleHsp" style=""></span>mL/min/1.73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span> with very high albuminuria.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">6</span></a> On the other hand, the main data of the FIGARO-DKD trial demonstrated that with a mean eGFR of 67.6<span class="elsevierStyleHsp" style=""></span>mL/min/1.73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span> with high and very high albuminuria, finerenone therapy improved cardiovascular outcome compared to placebo predominantly at expenses of improving in hospitalization for heart failure and death. With respect to renal outcomes there was a trend in favor of protection that did not attained statistical significance.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">7</span></a> However, when the analysis of the whole database was performed in the FIDELITY trial, it was found that finerenone reduces clinically relevant cardiovascular and kidney outcomes across the spectrum of CKD in patients with T2D.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Other advantages of the use of finerenone are: (1) important reduction of hyperkalemia providing a basis for clinical use of the drug<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">9</span></a>; (2) prevention of atrial fibrillation<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">10</span></a>; (3) prevention of incident of heart failure<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">11</span></a>; (4) primary and secondary cardiovascular prevention.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a> On the other hand, a percentage of patients in both FIDELIO-DKD and FIGARO-DKD trials received at baseline treatment with a sodium-glucose cotransporter-2 inhibitors (SGLT2i) or glucagon-like peptide-1 agonists (GLP1a) it has been demonstrated that these drugs do not interfere at all with the positive effect of finerenone indicating that an additive effect of the combination any of these two drugs with finerenone is very probable.<a class="elsevierStyleCrossRefs" href="#bib0155"><span class="elsevierStyleSup">12,13</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">T2D particularly when CKD is present is accompanied by a significant increase in BP that we need to control. In the current trials, the great majority of patients were receiving three or more drugs at baseline.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a> In other words, many of them presented with resistant hypertension. The mean baseline systolic BP was 136.8<span class="elsevierStyleHsp" style=""></span>mmHg in FIDELITY trial that was elevated according to the goal promoted by recent hypertension guidelines (BP<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>130/80<span class="elsevierStyleHsp" style=""></span>mmHg), and defended as adequate for resistant hypertension in the analysis of The Systolic Blood Pressure Intervention Trial (SPRINT) trial.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">14</span></a> The maximal effect of finerenone on systolic BP was −3.84<span class="elsevierStyleHsp" style=""></span>mmHg in office BP observed at month fourth.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">15</span></a> Apparently, this fall in systolic BP was insufficient to attain the expected goal according to hypertension guidelines, particularly whether KDIGO guidelines are considered because the goal for systolic BP in CKD is <120<span class="elsevierStyleHsp" style=""></span>mmHg.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">16</span></a> However, data from the substudy of ambulatory BP monitoring (ABPM) performed in the Mineralocorticoid Receptor Antagonist Tolerability Study in Diabetic Nephropathy ARTS-DN trial showed that finerenone reduced 24<span class="elsevierStyleHsp" style=""></span>h, daytime and nighttime systolic BP with a placebo adjusted change at the end of the study above −8.3<span class="elsevierStyleHsp" style=""></span>mmHg for 10, 15 and 20<span class="elsevierStyleHsp" style=""></span>mg of finerenone per day,<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">17</span></a> clearly above the fall in BP obtained in the office in these trials.</p><p id="par0030" class="elsevierStylePara elsevierViewall">Finally, clinicians interested in the treatment of DKD probably consider after reading the results of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">18</span></a> that a SGLT2i could be better for renal protection than finerenone (30% compares with 18%). However, the recent publication showing the comparison in the evolution of patients in FIDELITY accomplishing the entry criteria of CREDENCE trial proved that the comparison was 30% to 28%.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">19</span></a> These data indicate that the selection of patients in trials must accomplish similar criteria to avoid false differences in the outcome.</p><p id="par0035" class="elsevierStylePara elsevierViewall">In conclusion, finerenone is a new drug that comes to improve the cardiorenal prognosis of patients with DKD adding its effects to those of RAS blockers, SGLT2i, and GLP1a.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:19 [ 0 => array:3 [ "identificador" => "bib0100" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.E. Alexandrou" 1 => "A. Papagianni" 2 => "A. Tsapas" 3 => "C. Loutradis" 4 => "A. Boutou" 5 => "A. Piperidou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/HJH.0000000000002187" "Revista" => array:6 [ "tituloSerie" => "J Hypertens" "fecha" => "2019" "volumen" => "37" "paginaInicial" => "2307" "paginaFinal" => "2324" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31688290" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0105" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The time has come for systematic screening for primary aldosteronism in all hypertensives" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "G. Maiolino" 1 => "L.A. Calò" 2 => "G.P. Rossi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2017.02.041" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2017" "volumen" => "69" "paginaInicial" => "1821" "paginaFinal" => "1823" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28385311" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0110" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L.M. Ruilope" 1 => "G. Ruiz-Hurtado" 2 => "J. Tamargo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.tcm.2021.04.003" "Revista" => array:6 [ "tituloSerie" => "Trends Cardiovasc Med" "fecha" => "2022" "volumen" => "32" "paginaInicial" => "234" "paginaFinal" => "236" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33872758" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0115" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Bärfacker" 1 => "A. Kuhl" 2 => "A. Hillisch" 3 => "R. Grosser" 4 => "S. Figueroa-Pérez" 5 => "H. Heckroth" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/cmdc.201200081" "Revista" => array:6 [ "tituloSerie" => "ChemMedChem" "fecha" => "2012" "volumen" => "7" "paginaInicial" => "1385" "paginaFinal" => "1403" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22791416" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0120" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.L. Bakris" 1 => "R. Agarwal" 2 => "J.C. Chan" 3 => "M.E. Cooper" 4 => "R.T. Gansevoort" 5 => "H. Haller" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.2015.10081" "Revista" => array:6 [ "tituloSerie" => "JAMA" "fecha" => "2015" "volumen" => "314" "paginaInicial" => "884" "paginaFinal" => "894" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26325557" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0125" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.L. Bakris" 1 => "R. Agarwal" 2 => "S.D. Anker" 3 => "B. Pitt" 4 => "L.M. Ruilope" 5 => "P. Rossing" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa2025845" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2020" "volumen" => "383" "paginaInicial" => "2219" "paginaFinal" => "2229" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33264825" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0130" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiovascular events with finerenone in kidney disease and type 2 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Pitt" 1 => "G. Filippatos" 2 => "R. Agarwal" 3 => "S.D. Anker" 4 => "G.L. Bakris" 5 => "P. Rossing" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa2110956" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2021" "volumen" => "385" "paginaInicial" => "2252" "paginaFinal" => "2263" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34449181" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0135" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Agarwal" 1 => "G. Filippatos" 2 => "B. Pitt" 3 => "S.D. Anker" 4 => "P. Rossing" 5 => "A. Joseph" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehab777" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2022" "volumen" => "43" "paginaInicial" => "474" "paginaFinal" => "484" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35023547" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0140" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Agarwal" 1 => "A. Joseph" 2 => "S.D. Anker" 3 => "G. Filippatos" 4 => "P. Rossing" 5 => "L.M. Ruilope" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1681/ASN.2021070942" "Revista" => array:6 [ "tituloSerie" => "J Am Soc Nephrol" "fecha" => "2022" "volumen" => "33" "paginaInicial" => "225" "paginaFinal" => "237" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34732509" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0145" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Filippatos" 1 => "G.L. Bakris" 2 => "B. Pitt" 3 => "R. Agarwal" 4 => "P. Rossing" 5 => "L.M. Ruilope" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2021.04.079" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2021" "volumen" => "78" "paginaInicial" => "142" "paginaFinal" => "152" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34015478" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0150" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD Trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Filippatos" 1 => "S.D. Anker" 2 => "R. Agarwal" 3 => "L.M. Ruilope" 4 => "P. Rossing" 5 => "G.L. Bakris" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/CIRCULATIONAHA.121.057983" "Revista" => array:6 [ "tituloSerie" => "Circulation" "fecha" => "2022" "volumen" => "145" "paginaInicial" => "437" "paginaFinal" => "447" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34775784" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0155" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Rossing" 1 => "G. Filippatos" 2 => "R. Agarwal" 3 => "S.D. Anker" 4 => "B. Pitt" 5 => "L.M. Ruilope" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ekir.2021.10.008" "Revista" => array:6 [ "tituloSerie" => "Kidney Int Rep" "fecha" => "2022" "volumen" => "7" "paginaInicial" => "36" "paginaFinal" => "45" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35005312" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0160" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by GLP-1RA use" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Rossing" 1 => "R. Agarwal" 2 => "S.D. Anker" 3 => "G. Filippatos" 4 => "B. Pitt" 5 => "L.M. Ruilope" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Diabetes Obes Metab" "fecha" => "2022" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0165" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Optimal systolic blood pressure target in resistant hypertension" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "B.M. Egan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.amjmed.2019.02.028" "Revista" => array:5 [ "tituloSerie" => "Am J Med" "fecha" => "2019" "volumen" => "132" "paginaInicial" => "e623" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31400795" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0170" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L.M. Ruilope" 1 => "R. Agarwal" 2 => "S.D. Anker" 3 => "G. Filippatos" 4 => "B. Pitt" 5 => "P. Rossing" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/HYPERTENSIONAHA.122.19744" "Revista" => array:6 [ "tituloSerie" => "Hypertension" "fecha" => "2022" "volumen" => "79" "paginaInicial" => "2685" "paginaFinal" => "2695" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36252131" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0175" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical practice guideline for diabetes management in chronic kidney disease" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.kint.2022.06.008" "Revista" => array:6 [ "tituloSerie" => "Kidney Int" "fecha" => "2022" "volumen" => "102" "paginaInicial" => "S1" "paginaFinal" => "S127" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36272764" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0180" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Agarwal" 1 => "L.M. Ruilope" 2 => "G. Ruiz-Hurtado" 3 => "H. Haller" 4 => "R.E. Schmieder" 5 => "S.D. Anker" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "J Hypertens" "fecha" => "2022" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0185" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Canagliflozin and renal outcomes in type 2 diabetes and nephropathy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Perkovic" 1 => "M.J. Jardine" 2 => "B. Neal" 3 => "S. Bompoint" 4 => "H.J.L. Heerspink" 5 => "D.M. Charytan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1811744" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2019" "volumen" => "380" "paginaInicial" => "2295" "paginaFinal" => "2306" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30990260" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0190" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Agarwal" 1 => "S.D. Anke" 2 => "G. Filippatos" 3 => "B. Pitt" 4 => "P. Rossing" 5 => "L.M. Ruilope" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ndt/gfab336" "Revista" => array:6 [ "tituloSerie" => "Nephrol Dial Transplant" "fecha" => "2022" "volumen" => "37" "paginaInicial" => "1261" "paginaFinal" => "1269" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34850173" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/18891837/0000004000000002/v3_202307241519/S1889183722000848/v3_202307241519/en/main.assets" "Apartado" => array:4 [ "identificador" => "9102" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/18891837/0000004000000002/v3_202307241519/S1889183722000848/v3_202307241519/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1889183722000848?idApp=UINPBA00004N" ]
Información de la revista
Compartir
Descargar PDF
Más opciones de artículo
Editorial
Counteracting aldosterone in cardiorenal disease in type 2 diabetes through finerenone administration
Contrarrestar la aldosterona en la enfermedad cardiorrenal en la diabetes tipo 2 mediante la administración de finerenona